<DOC>
	<DOCNO>NCT02077868</DOCNO>
	<brief_summary>The purpose trial prove efficacy safety MGN1703 maintenance therapy first-line chemotherapeutic treatment metastatic colorectal cancer .</brief_summary>
	<brief_title>Evaluation MGN1703 Maintenance Treatment Patients With mCRC With Tumor Reduction During Induction Treatment</brief_title>
	<detailed_description>Due toxicity chemotherapeutic medication treatment break common practice treatment metastatic colorectal cancer . During treatment break variety maintenance treatment available . MGN1703 develop help Patient recover chemotherapy also boost patient 's immune System thus help effectively fight Tumor . After concept already prove previous study Trial conduct evaluate safety efficacy MGN1703 Treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Signed write informed consent Male female patient 18 year old Histologically confirm diagnosis colorectal cancer present unresectable stage IV ( UICC ) disease ( primary tumor may present ) Complete partial response , assess local investigator accord RECIST 1.1 , within 1230 week start induction treatment standard firstline chemotherapy without biological agent ECOG PS 01 Haematology biochemistry laboratory result within limit normally expect patient population recover receive induction treatment Male female patient childbearing potential ( i.e . undergo surgical sterilization hysterectomy , bilateral tubal ligation , bilateral oophorectomy postmenopausal least 24 consecutive month ) must use effective method contraception . Females child bear potential must negative serum pregnancy test History malignant tumor within last 5 year , except basal cell carcinoma curatively excise cervical carcinoma situ Known brain metastasis ( present treat ) Contraindication receive MGN1703 per current investigator brochure Known hypersensitivity component study product Prior allogeneic stem cell transplantation organ transplantation Active uncontrolled infection undiagnosed febrile condition Severe anemia require repeat blood cell transfusion Preexisting autoimmune antibodymediated disease immune deficiency Chronic systemic immune therapy immunosuppressant medication steroid within last 6 week ; continuous systemic steroid treatment within last 2 week prior start study treatment Use systemic antibiotic therapy within last 2 week prior start study treatment Inadequate pulmonary function accord Investigator 's judgment , history interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan HIV seropositivity active HBV/HCV infection Serious concomitant disease medical condition judgment investigator render patient high risk treatment complication Female patient pregnant breast feed Contraindication receive plan standard maintenance treatment accord applicable SmPC Treatment anticancer investigational drug within 12 month prior study treatment participation another clinical study investigational drug within 28 day prior study treatment Vaccination within 1 month prior start study treatment Any medical , mental , psychological psychiatric condition opinion investigator would permit patient complete study understand patient information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CRC</keyword>
	<keyword>mCRC</keyword>
	<keyword>maintenance treatment</keyword>
	<keyword>immune modulation</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>metastatic</keyword>
</DOC>